Patient With Lung Cancer: A Practical Guide to Diagnosis and Care Options

A patient with lung cancer faces a steep learning curve: unfamiliar terminology, fast-moving treatment decisions, and the question of where care can be delivered most effectively. This guide walks through what the diagnosis usually involves, who needs which tests, how treatment is organized, and what self-pay international patients should know about lung cancer care in China.

Understanding the Patient With Lung Cancer

Lung cancer is the leading cause of cancer death worldwide, with roughly 2.5 million new cases diagnosed each year. The disease is divided into two large categories. Non-small cell lung cancer (NSCLC) accounts for about 85 percent of cases and includes adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Small cell lung cancer (SCLC) makes up the remaining 15 percent and behaves more aggressively.

Modern lung cancer care no longer treats the disease as a single illness. Pathology now drives every major decision: tumor type, molecular markers (EGFR, ALK, ROS1, KRAS, PD-L1), and stage together determine which surgery, drug, or radiation strategy is offered. A patient with lung cancer in 2026 typically receives a more individualized treatment plan than was possible a decade ago.

Who Needs the Full Diagnostic Workup

Anyone with a confirmed or strongly suspected lung cancer diagnosis needs a comprehensive workup before treatment can begin. Common scenarios:

• A nodule found on screening low-dose CT that grows or develops suspicious features.
• A symptomatic patient with cough, hemoptysis, weight loss, or chest pain whose chest CT shows a mass.
• A patient with metastatic disease whose primary appears to be in the lung.
• A previously treated patient with rising tumor markers or new symptoms suggesting recurrence.

In each case the goals are the same: confirm the diagnosis with tissue, characterize the tumor biology, and stage the disease accurately enough to plan treatment.

How the Workup Is Performed

A standard contemporary workup for a patient with lung cancer typically includes:

1. Contrast chest CT to map the primary tumor and mediastinal lymph nodes.
2. PET-CT for staging beyond the chest, especially to detect distant metastases.
3. Brain MRI because the brain is a common site of metastasis and CT misses small lesions.
4. Tissue biopsy by bronchoscopy with endobronchial ultrasound (EBUS-TBNA) for central lesions or CT-guided needle biopsy for peripheral lesions.
5. Molecular profiling of the tissue: at minimum EGFR, ALK, ROS1, BRAF, KRAS, MET, RET, NTRK, and PD-L1; comprehensive next-generation sequencing where available.
6. Pulmonary function tests if surgery or radiation is being considered.
7. Multidisciplinary tumor board review before the treatment plan is finalized.

Skipping any step can lead to suboptimal treatment. A 65-year-old with adenocarcinoma and an EGFR exon 19 deletion, for example, may benefit far more from oral targeted therapy than from immediate chemotherapy.

Cost and Access

Cash prices for the diagnostic workup vary widely:

• United States cash for full workup (CT, PET-CT, brain MRI, EBUS biopsy with pathology, molecular panel): $15,000 to $35,000, typically billed in fragments by hospital and pathology lab.
• United Kingdom private: GBP 8,000 to 18,000 ($10,000 to $23,000).
• Singapore: SGD 15,000 to 25,000 ($11,000 to $18,500).
• Mainland China tier-1 hospitals: CNY 25,000 to 45,000 (roughly $3,600 to $6,400 at the 7:1 ratio) for the comprehensive workup, including molecular panel.

Treatment costs diverge even more sharply. A year of a branded targeted therapy can cost over $150,000 in the US compared with $15,000 to $40,000 in China, where the same molecules are available either as licensed originator products or as approved generics depending on patent status.

For a tailored cost estimate based on your pathology and stage, our team can prepare a written quote.

What Results Mean

Each piece of the workup answers a specific question. Imaging defines anatomic extent: where the tumor is, how big it is, which lymph nodes are involved, whether there are distant metastases. Pathology confirms the diagnosis and subtype. Molecular profiling determines whether targeted drugs or immunotherapy are options. Pulmonary function tests determine whether surgery or radiation is technically feasible.

A patient with lung cancer should leave the workup understanding three things: the stage in plain language (I to IV), whether any actionable molecular targets were found, and what the proposed first-line treatment is. If any of those is unclear, more conversation with the oncologist is needed before consent.

Next Steps for International Patients

For international patients considering care in China, a typical pathway:

1. Send pathology slides, prior imaging, and the existing molecular report (if any) for pre-arrival review.
2. Pre-arrival video consultation with a thoracic oncologist to agree on the plan.
3. Travel to the host city for the initial visit (4 to 7 days for diagnostics and treatment planning).
4. Begin treatment locally or take the written plan home to execute in the home country.

The most experienced Chinese centers for lung cancer include Fudan University Shanghai Cancer Center, Sun Yat-sen University Cancer Center in Guangzhou, the Cancer Hospital of the Chinese Academy of Medical Sciences in Beijing, West China Hospital in Chengdu, and HKU-Shenzhen Hospital. All have thoracic oncology departments staffed by surgeons, medical oncologists, radiation oncologists, and pathologists experienced in international cases.

Frequently Asked Questions

How long does the full lung cancer workup take in China?
For a coordinated visit, the full workup including imaging, biopsy, molecular panel, and tumor board review usually fits inside 5 to 7 working days. A second visit may be needed once molecular results return if those results redirect the treatment plan.

Can I get my US or UK pathology re-read in China?
Yes. Most top centers prefer to re-cut and re-stain submitted slides in their own pathology lab to ensure consistency with their treatment protocols. Patients should bring physical slides and the existing report.

Will my home oncologist accept the Chinese treatment plan?
A structured English report citing internationally recognized guidelines (NCCN, ESMO) is usually accepted as a basis for continuing care abroad. Many patients in fact return home to continue oral targeted therapy after the diagnostic workup is completed in China.

Are clinical trials available?
Yes. China runs a growing number of registered Phase II and Phase III trials for lung cancer, especially in targeted therapy and immunotherapy. Eligibility depends on molecular profile and prior treatment; the host center can screen on the spot.

Need Help Booking?

SinoCareLink can pre-book your lung cancer workup at a top Chinese center, translate reports into English, and arrange airport pickup. Contact us for a free consultation.